Elanco Animal Health Incorporated

NYSE:ELAN Stock Report

Market Cap: US$6.4b

Elanco Animal Health Future Growth

Future criteria checks 0/6

Elanco Animal Health's earnings are forecast to decline at 0.7% per annum while its annual revenue is expected to grow at 3.8% per year. EPS is expected to decline by 4.7% per annum. Return on equity is forecast to be 8.9% in 3 years.

Key information

-0.7%

Earnings growth rate

-4.72%

EPS growth rate

Pharmaceuticals earnings growth14.6%
Revenue growth rate3.8%
Future return on equity8.95%
Analyst coverage

Good

Last updated13 May 2025

Recent future growth updates

Recent updates

Elanco: Deleveraging Takes Time

May 12

The Market Doesn't Like What It Sees From Elanco Animal Health Incorporated's (NYSE:ELAN) Revenues Yet As Shares Tumble 25%

Apr 09
The Market Doesn't Like What It Sees From Elanco Animal Health Incorporated's (NYSE:ELAN) Revenues Yet As Shares Tumble 25%

Elanco Animal Health: Even Cheaper, Still Not A Buy

Mar 31
author-image

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Mar 17 Strategic divestment and product launches are enhancing financial stability by reducing debt and increasing investment capacity, aiming to improve net margins.

Elanco Animal Health: Building On Success

Jan 15

Elanco Animal Health (NYSE:ELAN) Takes On Some Risk With Its Use Of Debt

Jan 08
Elanco Animal Health (NYSE:ELAN) Takes On Some Risk With Its Use Of Debt

Elanco Animal Health Incorporated's (NYSE:ELAN) Business And Shares Still Trailing The Industry

Dec 12
Elanco Animal Health Incorporated's (NYSE:ELAN) Business And Shares Still Trailing The Industry

Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals

Nov 15
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals

Elanco Animal Health: Not Expensive, But Debt Remains An Issue

Nov 08

Here's Why Elanco Animal Health (NYSE:ELAN) Has A Meaningful Debt Burden

Sep 22
Here's Why Elanco Animal Health (NYSE:ELAN) Has A Meaningful Debt Burden

Elanco Animal Health Incorporated (NYSE:ELAN) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Sep 01
Elanco Animal Health Incorporated (NYSE:ELAN) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Elanco Animal Health: Positioned For Success

Aug 16

Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%

Jul 11
Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%

Elanco Animal Health: Pipeline Concerns Appear Overblown

Jun 30

Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet

Jun 06
Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet

Elanco Animal Health: At Least Fully Valued After Rally

Jun 05

Elanco Animal Health: A Solid Sale Addresses Leverage

Feb 09

Elanco Animal Health: Turning More Healthy

Dec 21

Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile

Oct 05

Elanco Animal Health: Seems Like A Decent Bet Right Now

Jul 25

Elanco Animal Health: Robust Results Overshadowed By Persisting Challenges

Jul 14

Earnings and Revenue Growth Forecasts

NYSE:ELAN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274,9141375465199
12/31/20264,7264745843611
12/31/20254,519-741125811
3/31/20254,427373333535N/A
12/31/20244,439338380541N/A
9/30/20244,454205372521N/A
6/30/20244,492-1,255425557N/A
3/31/20244,365-1,302278418N/A
12/31/20234,417-1,231117271N/A
9/30/20234,367-1,144-65127N/A
6/30/20234,324-113-87118N/A
3/31/20234,442-26173369N/A
12/31/20224,411-78268452N/A
9/30/20224,538-132466662N/A
6/30/20224,644-171387562N/A
3/31/20224,748-371232399N/A
12/31/20214,764-483286483N/A
9/30/20214,791-698-86167N/A
6/30/20214,550-729-366-34N/A
3/31/20213,857-572-345-23N/A
12/31/20203,271-574-352-41N/A
9/30/20202,921-246-97178N/A
6/30/20202,802-101147330N/A
3/31/20202,998-138220N/A
12/31/20193,0716827224N/A
9/30/20193,0839489237N/A
6/30/20193,073144207362N/A
3/31/20193,06245314448N/A
12/31/20183,06787N/A487N/A
9/30/20183,022-91N/A355N/A
6/30/20182,958-172N/A267N/A
3/31/20182,906-174N/A176N/A
12/31/20172,889-311N/A174N/A
12/31/20162,914-48N/A156N/A
12/31/20152,909-211N/A7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELAN's earnings are forecast to decline over the next 3 years (-0.7% per year).

Earnings vs Market: ELAN's earnings are forecast to decline over the next 3 years (-0.7% per year).

High Growth Earnings: ELAN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ELAN's revenue (3.8% per year) is forecast to grow slower than the US market (8.5% per year).

High Growth Revenue: ELAN's revenue (3.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ELAN's Return on Equity is forecast to be low in 3 years time (8.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 07:19
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Elanco Animal Health Incorporated is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Ishan MajumdarBaptista Research
Ardalan ArfaeiBMO Capital Markets Equity Research